- Home
- DSM vs ITOS Comparison
DSM vs ITOS Comparison
Compare DSM & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ITOS
- Stock Information
- Founded
- DSM 1989
- ITOS 2011
- Country
- DSM United States
- ITOS United States
- Employees
- DSM N/A
- ITOS N/A
- Industry
- DSM Investment Managers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DSM Finance
- ITOS Health Care
- Exchange
- DSM Nasdaq
- ITOS Nasdaq
- Market Cap
- DSM 275.8M
- ITOS 381.2M
- IPO Year
- DSM N/A
- ITOS 2020
- Fundamental
- Price
- DSM $5.63
- ITOS $9.99
- Analyst Decision
- DSM
- ITOS Hold
- Analyst Count
- DSM 0
- ITOS 6
- Target Price
- DSM N/A
- ITOS $10.60
- AVG Volume (30 Days)
- DSM 161.7K
- ITOS 1.0M
- Earning Date
- DSM 01-01-0001
- ITOS 08-07-2025
- Dividend Yield
- DSM 3.97%
- ITOS N/A
- EPS Growth
- DSM N/A
- ITOS N/A
- EPS
- DSM N/A
- ITOS N/A
- Revenue
- DSM N/A
- ITOS $35,000,000.00
- Revenue This Year
- DSM N/A
- ITOS N/A
- Revenue Next Year
- DSM N/A
- ITOS N/A
- P/E Ratio
- DSM N/A
- ITOS N/A
- Revenue Growth
- DSM N/A
- ITOS 177.89
- 52 Week Low
- DSM $4.69
- ITOS $4.80
- 52 Week High
- DSM $6.05
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- DSM 43.93
- ITOS 62.26
- Support Level
- DSM $5.56
- ITOS $9.91
- Resistance Level
- DSM $5.60
- ITOS $10.20
- Average True Range (ATR)
- DSM 0.04
- ITOS 0.16
- MACD
- DSM 0.00
- ITOS -0.12
- Stochastic Oscillator
- DSM 25.00
- ITOS 13.56
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.